Governance Avacta Group Plc

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:04 15/07/2026 BST			5-day change	1st Jan Change
69.00 ^GBX	0.00%		-2.13%	+18.97%

07-09	Avacta appoints "seasoned" new deputy chair	AN
07-09	Avacta Group Settles Accelerated Payment Under Convertible Bond	MT

Executive Committee: Avacta Group Plc

Manager

Positions heldSince

Christina Coughlin

56 year

Chief Executive Officer

31/03/2024

Brian Hahn

51 year

Director of Finance/CFO	21/01/2025
Corporate Secretary	21/01/2025

David Liebowitz

Chief Tech/Sci/R&D Officer

30/06/2025

Karen Harrison

Chief Operating Officer

Francis X. Wilson

Chief Tech/Sci/R&D Officer

08/02/2026

Composition of the Board of Directors: Avacta Group Plc

Director

CommitteesSince

Richard Hughes

58 year

Chairman	21/06/2026
Independent Dir/Board Member	27/05/2025

Patrick Volkert Vink

62 year

Compensation Committee
Governance Committee Chair
Nominating Committee Chair
Audit Committee
Compensation Committee Chair	27/07/2021

Paul Fry

60 year

Compensation Committee	02/02/2020
Audit Committee Chair	02/02/2020

Mark Goldberg

71 year

Compensation Committee Chair

30/04/2025

David Bryant

59 year

Director/Board Member	27/05/2025
Independent Dir/Board Member	27/05/2025

Christina Coughlin

56 year

Director/Board Member

17/03/2022

Latest Appointments: Avacta Group Plc

07-08	Avacta Group plc Announces Appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director	CI
05-29	Avacta Group plc Announces Board Changes	CI
02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	Avacta Therapeutics Names Chemistry Vice President as Chief Scientific Officer	MT
02-09	Avacta Therapeutics Announces Executive Changes	CI
22/09/25	CORRECT (Sep 01): hVIVO appoints Avacta Chair Shaun Chilton to board	AN
01/09/25	HVIVO appoints Avacta Chair Shaun Chilton to lead board	AN

More news

Former Officers and Directors: Avacta Group Plc

Insider

Positions held

SinceUntil

Shaun Chilton

Director/Board Member	18/06/2023	23/06/2024
Chairman	23/06/2024	21/06/2026
Independent Dir/Board Member	18/06/2023	21/06/2026

Michelle Morrow

Chief Tech/Sci/R&D Officer	03/11/2024	08/02/2026
Corporate Officer/Principal	14/10/2024	03/11/2024

Darlene Deptula-Hicks

Director/Board Member

25/06/2024

30/06/2025

Trevor Nicholls

Director/Board Member	10/06/2018	29/04/2025
Chairman	01/08/2013	10/06/2018
Independent Dir/Board Member	01/08/2013	29/04/2025

Tony Gardiner

Director/Board Member	03/01/2016	12/01/2025
Director of Finance/CFO	03/01/2016	12/01/2025

Eliot Forster

Chairman

10/06/2018

19/06/2024

Fiona McLaughlin

Chief Tech/Sci/R&D Officer	-	31/05/2024
Corporate Officer/Principal	01/09/2021	-

David Alastair Smith

Director/Board Member	31/12/2004	30/04/2024
Chief Executive Officer	31/12/2004	30/04/2024
Founder	31/12/2003	30/04/2024

Simon Bennett

Corporate Officer/Principal

18/12/2023

Neil Bell

Corporate Officer/Principal

30/06/2020

30/11/2023

Joanne Soundy

Sales & Marketing

31/10/2020

31/07/2022

Rob Ford

Corporate Officer/Principal

31/07/2020

31/03/2022

Chris Miller

Corporate Officer/Principal

30/11/2017

31/03/2022

Fran Mullen

Corporate Officer/Principal

31/07/2017

31/10/2021

Michael Owen

Director/Board Member	16/09/2015	23/03/2021
Independent Dir/Board Member	-	23/03/2021

Samuel Cameron Williams

Director/Board Member

27/01/2019

03/11/2019

Alan Aubrey

Director/Board Member

12/07/2006

20/01/2019

Jose Saro

Chief Tech/Sci/R&D Officer

11/12/2018

Michael Albin

Director/Board Member

04/02/2014

29/03/2018

Philippe Cotrel

Corporate Officer/Principal

24/01/2016

Timothy Sykes

Director/Board Member	23/12/2010	09/12/2015
Director of Finance/CFO	31/03/2006	09/12/2015
Corporate Secretary	07/02/2010	09/12/2015

Amrik Basran

Chief Tech/Sci/R&D Officer

28/02/2015

Gwynfor Humphreys

Director/Board Member	12/07/2006	22/01/2015
Chairman	23/12/2010	23/01/2014

Anthony William Robards

Director/Board Member

07/02/2010

23/01/2014

Matt Johnson

Chief Tech/Sci/R&D Officer	15/09/2013	-
Corporate Officer/Principal	30/04/2014	-

Richard Craig Alan Slater

Director/Board Member	31/05/2012	19/01/2017
Chief Operating Officer	31/05/2012	-
Director of Finance/CFO	06/07/2015	03/01/2016

Barry Porter

Director/Board Member

07/02/2010

16/03/2011

Daron R. Lee

Director/Board Member

06/08/2006

Russell Winston Hodgetts

Chief Operating Officer

30/09/2005

Simon Webster

Chief Tech/Sci/R&D Officer	07/02/2010	-
Founder	31/12/2003	-

Kurt Baldwin

Director/Board Member	31/12/2003	23/12/2010
Chief Tech/Sci/R&D Officer	23/12/2010	-
Founder	31/12/2003	-

Ged Holmes

Corporate Officer/Principal

Paul Ko Ferrigno

Chief Tech/Sci/R&D Officer

Alexander Stevenson

President

Age distribution of managers

Parity Men Women

Male	10
Female	1

Of which Executive Committee

Male	4
Female	1

Of which Directors

Male	6
Female	0

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Companyâ€™s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.

Employees

Sector

Biotechnology & Medical Research

More about the company